医疗器械公司AngioDynamics（ANGO）今日盘中股价大幅下挫5.2%，引发市场关注。
消息面上，公司近期重申2026财年全年业绩展望，预计关税政策将持续对其财务表现产生400万至600万美元的影响。这一预估与先前披露一致，反映出公司在全球供应链成本管理方面面临的挑战未获缓解，可能加剧了投资者对其盈利能力的担忧。
医疗器械公司AngioDynamics（ANGO）今日盘中股价大幅下挫5.2%，引发市场关注。
消息面上，公司近期重申2026财年全年业绩展望，预计关税政策将持续对其财务表现产生400万至600万美元的影响。这一预估与先前披露一致，反映出公司在全球供应链成本管理方面面临的挑战未获缓解，可能加剧了投资者对其盈利能力的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.